{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:22:27Z","timestamp":1789143747782,"version":"build-2803163510"},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T00:00:00Z","timestamp":1379635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Antiresorptive medications are essential in treating diseases of pathologic osteoclastic bone resorption, including bone cancer and osteoporosis. Bisphosphonates (BPs) are the most commonly used antiresorptives in clinical practice. Although inhibition of bone resorption is important in regulating unwanted malignant and metabolic osteolysis, BP treatment is associated with potential side effects, including osteonecrosis of the jaws (ONJ). Recently, non-BP antiresorptive medications targeting osteoclastic function and differentiation, such as denosumab, have entered the clinical arena. Denosumab treatment results in a similar rate of ONJ as BPs. Animal models of ONJ, using high-dose BP treatment in combination with tooth extraction or dental disease, provide valuable tools and insight in exploring ONJ pathophysiology. However, the ability of other antiresorptives to induce ONJ-like lesions in animal models has not been explored. Such studies would be beneficial in providing support for the role of osteoclast inhibition in ONJ pathogenesis versus a direct BP effect on oral tissues. Here, we tested the ability of the receptor activator of NF-\u03baB ligand (RANKL) inhibitors RANK-Fc (composed of the extracellular domain of RANK fused to the fragment crystallizable [Fc] portion of immunoglobulin G [IgG]) and OPG-Fc (composed of the RANKL-binding domains of osteoprotegerin [OPG] linked to the Fc portion of IgG) to induce ONJ in mice in the presence of periapical disease, but in the absence of dental extractions. We demonstrate radiographic evidence of ONJ in RANK-Fc\u2013treated and OPG-Fc\u2013treated mice, including inhibition of bone loss, increased bone density, lamina dura thickening, and periosteal bone deposition. These findings closely resembled the radiographic appearance of an ONJ patient on denosumab treatment. Histologic examination revealed that RANK-Fc treatment and OPG-Fc treatment resulted in absence of osteoclasts, periosteal bone formation, empty osteocytic lacunae, osteonecrosis, and bone exposure. In conclusion, we have successfully induced ONJ in mice with periapical disease, using potent osteoclast inhibitors other than BPs. Our findings, coupled with ONJ animal models using high-dose BPs, suggest that osteoclast inhibition is pivotal to the pathogenesis of ONJ. \u00a9 2014 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.2097","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T22:09:00Z","timestamp":1381529340000},"page":"843-854","source":"Crossref","is-referenced-by-count":90,"title":["RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease"],"prefix":"10.1093","volume":"29","author":[{"given":"Tara L","family":"Aghaloo","sequence":"first","affiliation":[{"name":"Division of Diagnostic and Surgical Sciences, School of DentistryUniversity of California, Los Angeles (UCLA)Los AngelesCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cheong","sequence":"additional","affiliation":[{"name":"Division of Diagnostic and Surgical Sciences, School of DentistryUniversity of California, Los Angeles (UCLA)Los AngelesCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Bezouglaia","sequence":"additional","affiliation":[{"name":"Division of Diagnostic and Surgical Sciences, School of DentistryUniversity of California, Los Angeles (UCLA)Los AngelesCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kostenuik","sequence":"additional","affiliation":[{"name":"Amgen Inc.Thousand OaksCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Atti","sequence":"additional","affiliation":[{"name":"Division of Diagnostic and Surgical Sciences, School of DentistryUniversity of California, Los Angeles (UCLA)Los AngelesCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Dry","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, David Geffen School of MedicineUniversity of California, Los Angeles (UCLA)Los AngelesCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Q","family":"Pirih","sequence":"additional","affiliation":[{"name":"Section of Periodontics, School of DentistryUniversity of California, Los Angeles (UCLA)Los AngelesCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tetradis","sequence":"additional","affiliation":[{"name":"Molecular Biology InstituteUniversity of California, Los Angeles (UCLA)Los AngelesCAUSA"},{"name":"Division of Diagnostic and Surgical Sciences, School of DentistryUniversity of California, Los Angeles (UCLA)Los AngelesCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,9,20]]},"reference":[{"issue":"1\u20134","key":"2024020318545115700_jbmr2097-bib-0001","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000151371","article-title":"Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench","volume":"189","author":"Allen","year":"2009","journal-title":"Cells Tissues Organs."},{"key":"2024020318545115700_jbmr2097-bib-0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2005.09.002","article-title":"Anti-tumour activity of zoledronic acid","volume":"31","author":"Clezardin","year":"2005","journal-title":"Cancer Treat Rev."},{"key":"2024020318545115700_jbmr2097-bib-0003","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1749-6632.2010.05835.x","article-title":"Potential pathophysiological mechanisms in osteonecrosis of the jaw","volume":"1218","author":"Landesberg","year":"2011","journal-title":"Ann N Y Acad Sci."},{"key":"2024020318545115700_jbmr2097-bib-0004","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2024020318545115700_jbmr2097-bib-0005","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/154405910708601102","article-title":"Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates","volume":"86","author":"Kimmel","year":"2007","journal-title":"J Dent Res."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0006","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S8756-3282(99)00197-0","article-title":"Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment","volume":"25","author":"Ito","year":"1999","journal-title":"Bone."},{"issue":"3","key":"2024020318545115700_jbmr2097-bib-0007","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1254\/jphs.FMJ05004X2","article-title":"Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts","volume":"100","author":"Suzuki","year":"2006","journal-title":"J Pharmacol Sci."},{"issue":"3","key":"2024020318545115700_jbmr2097-bib-0008","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","article-title":"Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity","volume":"98","author":"Shipman","year":"1997","journal-title":"Br J Haematol."},{"issue":"6","key":"2024020318545115700_jbmr2097-bib-0009","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/11585470-000000000-00000","article-title":"Safety of long-term bisphosphonate therapy for the management of osteoporosis","volume":"71","author":"Lewiecki","year":"2011","journal-title":"Drugs."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0010","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.rdc.2012.09.001","article-title":"Safety of bisphosphonates","volume":"38","author":"Orozco","year":"2012","journal-title":"Rheum Dis Clin North Am."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0011","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ocl.2013.01.001","article-title":"Bisphosphonate therapy and atypical fractures","volume":"44","author":"Saleh","year":"2013","journal-title":"Orthop Clin North Am."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0012","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0013","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone."},{"issue":"35","key":"2024020318545115700_jbmr2097-bib-0014","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol."},{"issue":"9768","key":"2024020318545115700_jbmr2097-bib-0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet."},{"issue":"9","key":"2024020318545115700_jbmr2097-bib-0016","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol."},{"issue":"8","key":"2024020318545115700_jbmr2097-bib-0017","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"2024020318545115700_jbmr2097-bib-0018","first-page":"21","article-title":"Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab","author":"Keaveny","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"9810","key":"2024020318545115700_jbmr2097-bib-0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet."},{"issue":"5","key":"2024020318545115700_jbmr2097-bib-0020","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol."},{"issue":"7","key":"2024020318545115700_jbmr2097-bib-0021","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00520-012-1461-4","article-title":"Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients","volume":"20","author":"Dranitsaris","year":"2012","journal-title":"Support Care Cancer."},{"key":"2024020318545115700_jbmr2097-bib-0022","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"10","key":"2024020318545115700_jbmr2097-bib-0023","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"9","key":"2024020318545115700_jbmr2097-bib-0024","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg."},{"issue":"11","key":"2024020318545115700_jbmr2097-bib-0025","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg."},{"issue":"1","key":"2024020318545115700_jbmr2097-bib-0026","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer."},{"issue":"6","key":"2024020318545115700_jbmr2097-bib-0027","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1600-0714.2011.01125.x","article-title":"Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone","volume":"41","author":"Abtahi","year":"2012","journal-title":"J Oral Pathol Med."},{"issue":"8","key":"2024020318545115700_jbmr2097-bib-0028","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/jbmr.379","article-title":"Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat","volume":"26","author":"Aghaloo","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2024020318545115700_jbmr2097-bib-0029","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2024020318545115700_jbmr2097-bib-0030","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.4317\/medoral.17150","article-title":"Extraction socket healing in rats treated with bisphosphonate: animal model for bisphosphonate related osteonecrosis of jaws in multiple myeloma patients","volume":"16","author":"Ali-Erdem","year":"2011","journal-title":"Med Oral Patol Oral Cir Bucal."},{"issue":"1","key":"2024020318545115700_jbmr2097-bib-0031","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2353\/ajpath.2010.090592","article-title":"Bisphosphonates cause osteonecrosis of the jaw-like disease in mice","volume":"177","author":"Bi","year":"2010","journal-title":"Am J Pathol."},{"issue":"9","key":"2024020318545115700_jbmr2097-bib-0032","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1600-0714.2010.00927.x","article-title":"An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats","volume":"39","author":"Lopez-Jornet","year":"2010","journal-title":"J Oral Pathol Med."},{"issue":"7","key":"2024020318545115700_jbmr2097-bib-0033","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jbmr.37","article-title":"Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice","volume":"25","author":"Kikuiri","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0034","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.oraloncology.2008.04.013","article-title":"Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients","volume":"45","author":"Sonis","year":"2009","journal-title":"Oral Oncol."},{"issue":"3","key":"2024020318545115700_jbmr2097-bib-0035","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bone.2012.04.020","article-title":"Bisphosphonate related osteonecrosis of the jaw: a minipig large animal model","volume":"51","author":"Pautke","year":"2012","journal-title":"Bone."},{"issue":"6","key":"2024020318545115700_jbmr2097-bib-0036","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.joms.2012.11.016","article-title":"Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone","volume":"71","author":"Allen","year":"2013","journal-title":"J Oral Maxillofac Surg."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0037","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0765.1981.tb00995.x","article-title":"The progress of the periodontal syndrome in the rice cat. II. The effects of a diphosphonate on the periodontium","volume":"16","author":"Gotcher","year":"1981","journal-title":"J Periodontal Res."},{"issue":"7","key":"2024020318545115700_jbmr2097-bib-0038","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/jbmr.1894","article-title":"Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice","volume":"28","author":"Kang","year":"2013","journal-title":"J Bone Miner Res."},{"key":"2024020318545115700_jbmr2097-bib-0039","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","article-title":"Antiresorptives and osteonecrosis of the jaw","volume":"12","author":"Yamashita","year":"2012","journal-title":"J Evid Based Dent Pract."},{"key":"2024020318545115700_jbmr2097-bib-0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0041","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2024020318545115700_jbmr2097-bib-0042","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"2024020318545115700_jbmr2097-bib-0043","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4049\/jimmunol.179.1.266","article-title":"Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection","volume":"179","author":"Miller","year":"2007","journal-title":"J Immunol."},{"issue":"10","key":"2024020318545115700_jbmr2097-bib-0044","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1177\/00220345910700100901","article-title":"Kinetics of bone-resorbing activity in developing periapical lesions","volume":"70","author":"Wang","year":"1991","journal-title":"J Dent Res."},{"issue":"7","key":"2024020318545115700_jbmr2097-bib-0045","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.4049\/jimmunol.165.7.3626","article-title":"IL-10, but not IL-4, suppresses infection-stimulated bone resorption in vivo","volume":"165","author":"Sasaki","year":"2000","journal-title":"J Immunol."},{"issue":"5","key":"2024020318545115700_jbmr2097-bib-0046","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/jbmr.080109","article-title":"RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats","volume":"23","author":"Ominsky","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2024020318545115700_jbmr2097-bib-0047","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0048","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch Biochem Biophys."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0049","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1034\/j.1600-0722.2003.00051.x","article-title":"Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth","volume":"111","author":"Fukushima","year":"2003","journal-title":"Eur J Oral Sci."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5483\/BMBRep.2011.44.2.129","article-title":"Modulation of TNFSF expression in lymphoid tissue inducer cells by dendritic cells activated with Toll-like receptor ligands","volume":"44","author":"Han","year":"2011","journal-title":"BMB Rep."},{"issue":"5","key":"2024020318545115700_jbmr2097-bib-0051","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.4049\/jimmunol.162.5.2562","article-title":"TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells","volume":"162","author":"Josien","year":"1999","journal-title":"J Immunol."},{"issue":"1","key":"2024020318545115700_jbmr2097-bib-0052","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2302\/kjm.58.29","article-title":"New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target","volume":"58","author":"Tat","year":"2009","journal-title":"Keio J Med."},{"issue":"6","key":"2024020318545115700_jbmr2097-bib-0053","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1172\/JCI10763","article-title":"Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection","volume":"106","author":"Teng","year":"2000","journal-title":"J Clin Invest."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0054","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1601-0825.2010.01718.x","article-title":"Osteoclasts and odontoclasts: signaling pathways to development and disease","volume":"17","author":"Wang","year":"2011","journal-title":"Oral Dis."},{"issue":"7","key":"2024020318545115700_jbmr2097-bib-0055","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor,is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S.A."},{"issue":"20","key":"2024020318545115700_jbmr2097-bib-0056","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1073\/pnas.200294797","article-title":"Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene","volume":"97","author":"Kim","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6717","key":"2024020318545115700_jbmr2097-bib-0057","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature."},{"issue":"1","key":"2024020318545115700_jbmr2097-bib-0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejcb.2008.06.004","article-title":"Pathophysiological roles of osteoprotegerin (OPG)","volume":"88","author":"Reid","year":"2009","journal-title":"Eur J Cell Biol."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0059","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s007740070018","article-title":"Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis","volume":"18","author":"Tsurukai","year":"2000","journal-title":"J Bone Miner Metab."},{"issue":"9","key":"2024020318545115700_jbmr2097-bib-0060","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1210\/endo.141.9.7634","article-title":"Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function","volume":"141","author":"Udagawa","year":"2000","journal-title":"Endocrinology."},{"issue":"3","key":"2024020318545115700_jbmr2097-bib-0061","first-page":"209","article-title":"RANK\/RANKL\/OPG: literature review","volume":"36","author":"Silva","year":"2011","journal-title":"Acta Reumatol Port."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0062","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2011.23","article-title":"Advances in osteoclast biology: old findings and new insights from mouse models","volume":"7","author":"Edwards","year":"2011","journal-title":"Nat Rev Rheumatol."},{"issue":"11","key":"2024020318545115700_jbmr2097-bib-0063","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.tem.2012.05.005","article-title":"New insights into osteoclastogenic signaling mechanisms","volume":"23","author":"Nakashima","year":"2012","journal-title":"Trends Endocrinol Metab."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0064","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell."},{"issue":"11","key":"2024020318545115700_jbmr2097-bib-0065","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.4049\/jimmunol.179.11.7497","article-title":"Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses","volume":"179","author":"Stolina","year":"2007","journal-title":"J Immunol."},{"issue":"7","key":"2024020318545115700_jbmr2097-bib-0066","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1359\/jbmr.090215","article-title":"One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength","volume":"24","author":"Ominsky","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0067","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2591.2012.02105.x","article-title":"The receptor activator of NF-kappaB ligand-osteoprotegerin system in pulpal and periapical disease","volume":"46","author":"Belibasakis","year":"2013","journal-title":"Int Endod J."},{"issue":"5","key":"2024020318545115700_jbmr2097-bib-0068","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.tripleo.2006.11.036","article-title":"Kinetics of RANKL, RANK and OPG expressions in experimentally induced rat periapical lesions","volume":"103","author":"Kawashima","year":"2007","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0069","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1034\/j.1600-0765.2003.00615.x","article-title":"Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis","volume":"38","author":"Crotti","year":"2003","journal-title":"J Periodontal Res."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/154405910408300216","article-title":"Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis","volume":"83","author":"Mogi","year":"2004","journal-title":"J Dent Res."},{"issue":"5","key":"2024020318545115700_jbmr2097-bib-0071","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1128\/IAI.00043-13","article-title":"Porphyromonas gingivalis infection-associated periodontal bone resorption is dependent on receptor activator of NF-kappaB ligand","volume":"81","author":"Han","year":"2013","journal-title":"Infect Immun."},{"issue":"11","key":"2024020318545115700_jbmr2097-bib-0072","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1600-051X.2011.01780.x","article-title":"Receptor activator of nuclear factor kappa B ligand antagonists inhibit tissue inflammation and bone loss in experimental periodontitis","volume":"38","author":"Yuan","year":"2011","journal-title":"J Clin Periodontol."},{"issue":"7","key":"2024020318545115700_jbmr2097-bib-0073","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1902\/jop.2007.070073","article-title":"RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis","volume":"78","author":"Jin","year":"2007","journal-title":"J Periodontol."},{"issue":"6","key":"2024020318545115700_jbmr2097-bib-0074","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2591.2010.01703.x","article-title":"Effect of alendronate on alveolar bone resorption and angiogenesis in rats with experimental periapical lesions","volume":"43","author":"Xiong","year":"2010","journal-title":"Int Endod J."},{"issue":"1","key":"2024020318545115700_jbmr2097-bib-0075","first-page":"3","article-title":"Bisphosphonates in periodontal treatment: a review","volume":"7","author":"Badran","year":"2009","journal-title":"Oral Health Prev Dent."},{"issue":"3","key":"2024020318545115700_jbmr2097-bib-0076","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D","article-title":"Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases","volume":"92","author":"Hofbauer","year":"2001","journal-title":"Cancer."},{"issue":"8","key":"2024020318545115700_jbmr2097-bib-0077","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2174\/1381612013397807","article-title":"Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption","volume":"7","author":"Kostenuik","year":"2001","journal-title":"Curr Pharm Des."},{"issue":"7","key":"2024020318545115700_jbmr2097-bib-0078","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0079","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bone.2011.03.769","article-title":"Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody","volume":"49","author":"Kostenuik","year":"2011","journal-title":"Bone."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0080","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2011.04.001","article-title":"Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys","volume":"49","author":"Ominsky","year":"2011","journal-title":"Bone."},{"issue":"3","key":"2024020318545115700_jbmr2097-bib-0081","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0082","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1211\/jpp.62.04.0009","article-title":"Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts","volume":"62","author":"Akiyama","year":"2010","journal-title":"J Pharm Pharmacol."},{"issue":"11","key":"2024020318545115700_jbmr2097-bib-0083","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/mt.2009.153","article-title":"Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice","volume":"17","author":"Cho","year":"2009","journal-title":"Mol Ther."},{"key":"2024020318545115700_jbmr2097-bib-0084","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.11134","article-title":"RANK-Fc: a therapeutic antagonist for RANK-L in myeloma","volume":"97","author":"Sordillo","year":"2003","journal-title":"Cancer."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0085","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bone.2009.06.011","article-title":"Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin","volume":"45","author":"Li","year":"2009","journal-title":"Bone."},{"issue":"5","key":"2024020318545115700_jbmr2097-bib-0086","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/pr.2012.118","article-title":"High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice","volume":"72","author":"Bargman","year":"2012","journal-title":"Pediatr Res."},{"issue":"3","key":"2024020318545115700_jbmr2097-bib-0087","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.bone.2009.10.028","article-title":"RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis","volume":"46","author":"Verdrengh","year":"2010","journal-title":"Bone."},{"issue":"4","key":"2024020318545115700_jbmr2097-bib-0088","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cytogfr.2006.04.002","article-title":"The role of the TRAIL\/TRAIL receptors system in hematopoiesis and endothelial cell biology","volume":"17","author":"Zauli","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"2024020318545115700_jbmr2097-bib-0089","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00018-008-8536-x","article-title":"Role of full-length osteoprotegerin in tumor cell biology","volume":"66","author":"Zauli","year":"2009","journal-title":"Cell Mol Life Sci."},{"issue":"2","key":"2024020318545115700_jbmr2097-bib-0090","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/jcp.21430","article-title":"Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway","volume":"216","author":"Chamoux","year":"2008","journal-title":"J Cell Physiol."},{"issue":"3","key":"2024020318545115700_jbmr2097-bib-0091","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1601-6343.2009.01456.x","article-title":"Mandibular necrosis in beagle dogs treated with bisphosphonates","volume":"12","author":"Burr","year":"2009","journal-title":"Orthod Craniofac Res."},{"issue":"1","key":"2024020318545115700_jbmr2097-bib-0092","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1834-7819.2003.tb00011.x","article-title":"Oral ulceration with bone sequestration","volume":"48","author":"Farah","year":"2003","journal-title":"Aust Dent J."},{"issue":"1","key":"2024020318545115700_jbmr2097-bib-0093","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.tripleo.2005.06.022","article-title":"Mandibular osteomyelitis and tooth exfoliation following zoster-CMV co-infection","volume":"101","author":"Meer","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2097","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/29\/4\/843\/56566106\/jbmr2097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/29\/4\/843\/56566106\/jbmr2097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:50:45Z","timestamp":1710341445000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/29\/4\/843-854\/7598990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,20]]},"references-count":93,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,9,20]]},"published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2097","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,4,1]]},"published":{"date-parts":[[2013,9,20]]}}}